Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Sichuan Biokin Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
SHSE:688506'
s EV-to-FCF Range Over the Past 10 Years
Min: -128.88 Med: -63.8 Max: 23.59
Current: -60.79
During the past 12 years, the highest EV-to-FCF of Sichuan Biokin Pharmaceutical Co was 23.59. The lowest was -128.88. And the median was -63.80.
SHSE:688506's EV-to-FCF is ranked worse than 100% of 568
companies
in the Drug Manufacturers industry
Industry Median: 19.915
vs SHSE:688506: -60.79
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sichuan Biokin Pharmaceutical Co (SHSE:688506) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sichuan Biokin Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Sichuan Biokin Pharmaceutical Co's share price for today is ¥238.62.
Sichuan Biokin Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-3.790.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sichuan Biokin Pharmaceutical Co EV-to-FCF Related Terms
Sichuan Biokin Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sichuan Biokin Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sichuan Biokin Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sichuan Biokin Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sichuan Biokin Pharmaceutical Co's EV-to-FCF falls into.
Sichuan Biokin Pharmaceutical Co's current Enterprise Value is ¥101,639 Mil.
Sichuan Biokin Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-1,588 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Biokin Pharmaceutical Co (SHSE:688506) has a EV-to-FCF of -63.99 as of Sep. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sichuan Biokin Pharmaceutical Co and its competitors. According to the industry distribution chart, Sichuan Biokin Pharmaceutical Co ranks #999999 out of 568 companies in the Drug Manufacturers industry.
Is Sichuan Biokin Pharmaceutical Co's EV-to-FCF too high?
Sichuan Biokin Pharmaceutical Co's current EV-to-FCF is -63.99. Based on the distribution chart, Sichuan Biokin Pharmaceutical Co ranks #999999 out of 568 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sichuan Biokin Pharmaceutical Co has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Biokin Pharmaceutical Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sichuan Biokin Pharmaceutical Co ranks #999999 out of 568 companies for EV-to-FCF. This places Sichuan Biokin Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 19.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.92, based on 568 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sichuan Biokin Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sichuan Biokin Pharmaceutical Co's current EV-to-FCF is -63.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Biokin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Biokin Pharmaceutical Co (SHSE:688506) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥287.73, compared to a current price of ¥238.62 — trading 17.1% below its estimated fair value. The current EV-to-FCF is -63.99. Sichuan Biokin Pharmaceutical Co's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sichuan Biokin Pharmaceutical Co (SHSE:688506), the current EV-to-FCF is -63.99 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sichuan Biokin Pharmaceutical Co (SHSE:688506) Overvalued in 2026?
Based on GuruFocus' analysis, Sichuan Biokin Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥238.62 is trading 17.1% below its estimated GF Value™ of ¥287.73.
GuruFocus considers Sichuan Biokin Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:688506:
EV-to-FCF: -63.99
GF Value™: ¥287.73 vs. price of ¥238.62 (17.1% below fair value)
No single metric tells the full story. See the SHSE:688506 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sichuan Biokin Pharmaceutical Co Ltd is a chemical drug and biological drug-based company that integrates drug research and development, production and marketing.
79GF Score
Get the complete analysis for SHSE:688506
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688506 has been successfully added to your 
